According to Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) announced a pre-increase in results for the first three quarters of 2026. The company's net profit attributable to shareholders of listed companies for the first three quarters of 2026 is expected to be between RMB 1,028 million and RMB 1,103 million, up about 170% to 190% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses is expected to be between RMB 662 million and RMB 743 million, up about 145% to 175% year on year.
During the reporting period, the company achieved a two-way breakthrough in net profit attributable to shareholders of listed companies after deducting non-recurring profits and losses compared to the same period last year, mainly due to: sales revenue from the API business increased sharply year on year; the domestic formulation business closely followed the previous eight batch collection policy window and added 12 selected products collected on the basis of stabilizing the market share of the original winning products to achieve two-way breakthroughs; the business performance and development quality of the US formulation business achieved remarkable results, turning losses into profits year over year; Valsartan won the European arbitration lawsuit The one received from Sandoz paid to the company Lawyers' fees, arbitration fees, and US tariff rebates affected profits; during the reporting period, the company continued to focus on superior R&D products in optimizing the R&D structure to accelerate the R&D process of innovative drug products and high-end complex generic drugs and API products with advanced R&D progress. While achieving rapid improvement in R&D efficiency, corresponding R&D expenses were reduced year-on-year, affecting profit growth.